Form 4: Agios Pharmaceuticals Director David Schenkein Reports Stock and Option Awards

Director David Schenkein reports the acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Summary

• On June 20, 2024, David Schenkein, a director of Agios Pharmaceuticals, acquired 2,120 restricted stock units (RSUs) and 11,774 stock options.
• The RSUs will vest on June 20, 2025, and each RSU represents a contingent right to receive one share of Agios Pharmaceuticals common stock.
• The stock options, also granted on June 20, 2024, vest as to 100% of the underlying shares on June 20, 2025, and expire on June 20, 2034.
• The exercise price of the stock options is $42.45.
• Following these transactions, Schenkein directly owns 2,120 restricted stock units and 11,774 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants, which is generally a positive sign of incentivizing management, but doesn't provide specific insights into the company's performance.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option and RSU grants are common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs as a positive sign, aligning management's interests with the company's long-term success.

Key Dates